4.6 Review

From hemoglobin allostery to hemoglobin-based oxygen carriers

Journal

MOLECULAR ASPECTS OF MEDICINE
Volume 84, Issue -, Pages -

Publisher

ELSEVIER
DOI: 10.1016/j.mam.2021.101050

Keywords

Hemoglobin; Hemoglobin-based oxygen carriers; Blood substitutes; Allostery; Cooperativity; Oxygen transport

Ask authors/readers for more resources

Hemoglobin plays a vital role in red blood cells, but when outside of these cells, it can cause adverse effects such as hypertension and nephrotoxicity. The development of hemoglobin-based oxygen carriers (HBOCs) as substitutes for blood transfusions has faced challenges, and so far, no HBOC has been approved by FDA and EMA. However, HBOCs have found successful applications in organ perfusion fluids.
Hemoglobin (Hb) plays its vital role through structural and functional properties evolutionarily optimized to work within red blood cells, i.e., the tetrameric assembly, well-defined oxygen affinity, positive cooperativity, and heterotropic allosteric regulation by protons, chloride and 2,3-diphosphoglycerate. Outside red blood cells, the Hb tetramer dissociates into dimers, which exhibit high oxygen affinity and neither cooperativity nor allosteric regulation. They are prone to extravasate, thus scavenging endothelial NO and causing hypertension, and cause nephrotoxicity. In addition, they are more prone to autoxidation, generating radicals. The need to overcome the adverse effects associated with cell-free Hb has always been a major hurdle in the development of substitutes of allogeneic blood transfusions for all clinical situations where blood is unavailable or cannot be used due to, for example, religious objections. This class of therapeutics, indicated as hemoglobin-based oxygen carriers (HBOCs), is formed by genetically and/or chemically modified Hbs. Many efforts were devoted to the exploitation of the wealth of biochemical and biophysical information available on Hb structure, function, and dynamics to design safe HBOCs, overcoming the negative effects of free plasma Hb. Unfortunately, so far, no HBOC has been approved by FDA and EMA, except for compassionate use. However, the unmet clinical needs that triggered intensive investigations more than fifty years ago are still awaiting an answer. Recently, HBOCs repositioning has led to their successful application in organ perfusion fluids.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available